Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”

Gelijkaardige items

• Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
  door: Scandura, Carmen, et al.
  Gepubliceerd in: (2020)
• Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
  door: Kaga, Kanya, et al.
  Gepubliceerd in: (2020)
• A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)
  door: Yamanishi, Tomonori, et al.
  Gepubliceerd in: (2020)
• Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
  door: Nazir, Jameel, et al.
  Gepubliceerd in: (2017)
• Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
  door: Parise, Hélène, et al.
  Gepubliceerd in: (2019)